whether "endogenous" or "reactive" need not concern us here-and that the disappearance of the compulsion is a direct consequence of the improvement in mood. We would need to examine a group of compulsive eaters who remained depressed after jejeunoileostomy to test this hypothesis and so far we have not found such a combination of features. Certainly, this explanation would be consistent with the conclusion that depression accompanying obesity is often consequential rather than causal. 
Introduction
The development of hypokalaemia may complicate long-term diuretic therapy (Talso and Carballo, 1960; Remenchick et al., 1966; George et al., 1973) , but since the total extracellular fluid space contains only 3% of the total body content of potassium plasma potassium levels may not accurately reflect the total body or intracellular potassium status (Healy et al., 1970; White, 1970; Flear, 1972; Graybiel and Sode, 1971) . We therefore used the only direct method of estimating total body potassium (T.B.K.), whole-body counting, to assess the influence of longterm treatment with frusemide in patients with normal and diminished renal function. As potassium supplements are given customarily with diuretics, often without reference to the status of T.B.K., their effectiveness was also examined.
Patients and Methods
Twenty-nine patients, with their consent, were included in the study and were divided into four groups according to renal function and whether or not they were receiving potassium supplements. The clinical details are summarized in table I. Patients in group 1 had essential hypertension and normal renal function and were treated with frusemide 40 mg daily for one year without potassium supplements. Patients in group 2 were similar but in addition to frusemide 40 mg daily they received effervescent potassium chloride 24 mEq daily for the first four months of treatment. Thereafter they continued on frusemide alone. Patients in group 3 had hypertension associated with renal disease, the range of endogenous creatinine clearance being 11-60 ml/min with a mean of 22 ml/min. They received frusemide 120 mg daily for one year without potassium supplements. Patients in group 4 also had renal impairment but had a higher mean rate of endogenous creatinine clearance (43 ml/min) and as well as frusemide 120 mg daily they received effervescent potassium chloride 24 mEq daily for the first four months and then continued on frusemide alone for a further eight months. None of the patients had cardiac failure or oedema of other origin and none had received a diuretic in the past two years. Other antihypertensive therapy was continued as before. No patients were receiving 3-blocker drugs and the distribution of antihypertensive therapy was not dissimilar in the groups.
At the beginning of the study baseline measurements were made of T.B.K. and the plasma concentration of potassium, urea, creatinine, uric acid, blood sugar, chloride, and CO2. Blood pressure was also recorded using a standard cuff sphygmomanometer. The Merlin mobile whole-body counter (Boddy, 1967) was used to estimate T.B.K. by measuring the 1-46-Mev gamma-rays of the naturally occurring endogenous 40K, which is a constant fraction of T.B.K. The calibration procedure described previously (Boddy et al., 1971) was applied. The coefficient of variation has been shown (Boddy et al., 1971 ) to be (Boddy et al., 1972) using the height and age and also the height, weight, and age of the patient.
The results were analysed statistically using a paired Student's t test on the individual's results obtained before and after the treatment periods.
Results
The total body potassium (T.B.K.) data for each patient is given in fig. 1 plasma potassium values fall below the lower limit of the normal range for our laboratory (3 5 mEq/l. Significant reductions in mean chloride values occurred in all groups at four months but there was no further decrease at 12 months (table III) . In fact comparison of the pretreatment mean chloride values with the 12-month values showed a significant reduction only in groups 2 and 3. No significant changes occurred in CO2 levels in groups 1, 2, and 4. In group 3 a slight increase in mean CO2 values was evident at four and 12 months.
Plasma urea, creatinine, and uric acid values before treatment and after 12 months are summarized in table V. Plasma urea rose in all groups and significantly in groups 1 and 3, the mean increases being 5-3 mg/100 ml and 9 0 mg/100 ml respectively. Plasma creatinine rose slightly in all groups, this being significant, however, only in group 4 where there was a mean increase of 0 5 mg/100 ml. Plasma uric acid rose significantly in all groups though at no time did any patient develop symptoms suggestive of gout. Hyperglycaemia or glycosuria were not detected in any patient at any time.
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There was a fall in the mean value of standing diastolic blood pressure of 5-8 mm Hg and 5-7 mm Hg in groups 1 and 2 respectively. The fall in mean value of blood pressure was more marked in the patients with diminished renal function (who received a higher dose of frusemide), decreases of 13-1 mm Hg and 12-3 mm Hg in standing diastolic pressure being recorded for groups 3 and 4 respectively. These results were significant at the 5% level but as previously indicated the readings were not taken under control conditions.
Discussion
No evidence of depletion of T.B.K. was found in any of the groups of patients in this study after continuous treatment with frusemide for one year. No other study of T.B.K. in patients treated with frusemide for a similar length of time has been reported, but in a shorter study Anderson et al. (1971) found no significant change in T.B.K. in hypertensive patients treated with frusemide 40 mg twice daily for 8 weeks. Healy et al. (1970) reported moderate reductions in total exchangeable potassium (T.E.K.) in hypertensive patients after 15 weeks treatment with frusemide 40 mg twice daily and it is interesting that the mean reduction in T.E.K. found (247 mEq, which is equivalent to 9 8 g potassium) is comparable to the reduction in mean T.B.K. seen in our group 1 at 16 weeks. The return to pretreatment values of T.B.K. in group 1 after 12 months of therapy was also interesting. These patients seemed to be in slight negative potassium balance during the early period of treatment, presumably due to increased urinary potassium losses. As treatment continued there may have been a lessening of urinary potassium losses despite the continuation of other effects of frusemide such as the hypotensive effect and the raised plasma uric acid levels. This phenomenon has been reported before with T.E.K. levels in hypertensive patients treated with thiazide diuretics (Talso and Carballo, 1960; Gifford et al., 1961) , and Talso and Carballo (1960) showed a reduction in urinary potassium excretion with prolonged therapy. This is analogous to the effect of diuretic therapy on exchangeable sodium levels since an initial reduction followed by a return to normal values has been well documented (Talso and Carballo, 1960; Bartorelli et al., 1966; Lauwers and Conway, 1960 ). An alternative but unproven explanation is that there may have been a compensatory rise in intestinal K absorption.
Though there were statistically significant reductions in plasma K values in groups 1 and 3 (who did not receive K supplements) it should be emphasized that the degree of reduction was about 0 3-0 5 mEq/l. and that the mean plasma K values in all groups remained in the normal range. Similar small reductions have been noted by other workers (Healy et al., 1970; Anderson et al., 1971) . The slight reduction in plasma potassium may have been the result of the transient reduction in T.B.K. but a further possible mechanism may have been a redistribution of extracellular fluid potassium, there being a slight shift into the cells consequent upon the mild hypochloraemic alkalosis produced by the diuretic (Talso and Carballo, 1960; Flear, 1972) . In the present study mean plasma chloride levels were lower in all groups at four months but only in groups 2 and 3 was the reduction significant at 12 months. Though a statistically significant rise in plasma CO2 content occurred only in group 3 there were some individual patients in other groups who showed small rises and the overall evidence may therefore be in favour of a redistribution phenomenon to account for the small reductions in plasma potassium level noted. The poor correlation between the slightly low plasma potassium levels in some patients and the ratio between the measured T.B.K. and expected T.B.K. confirms the view of many investigators (Healy et al., 1970; White, 1970; Flear, 1970; Graybiel and Sode, 1971) that the plasma potassium level is a relatively poor guide to the whole body potassium status. Edmonds and Jasani (1972) , however, reported a good correlation between plasma potassium levels and the ratio between measured T.B.K. (T.B.K.m) and expected T.B.K. (T.B.K.e) when all the patients studied were included in the analysis. The reason for this may be that most plasma potassium levels and T.B.K.m: T.B.K.e ratios were within the normal range, but it should be noted that several of the most depleted patients, many of whom had cardiac complications, had plasma potassium levels within the normal range. The results of this study clearly question the necessity for potassium supplementation in long term diuretic therapy with frusemide unless, of course, there is evidence of pre-existing potassium depletion or of some other factor such as cardiac failure, cirrhosis of the liver, or the nephrotic syndrome. It is irksome for patients to take three to eight potassium tablets a day, particularly if several other drugs, such as antihypertensive agents, are also being taken. Since it has been calculated (George et al., 1973 ) that 70% of patients attending one blood pressure clinic are on diuretic therapy the issue is potentially a large one with obvious economic implications. The evidence from this study is that when frusemide is given as an adjunct to antihypertensive therapy in non-oedematous patients who are not potassium depleted routine potassium supplements are not required. Also, when potassium supplements are given to patients with normal renal function who are not potassium depleted these are not retained (Bartorelli et al., 1966; Down et al., 1972) , which is in contrast to the situation in potassiumdepleted patients in whom retention of potassium supplements has been shown (McKenna et al., 1971) .
Thiazides are perhaps more commonly prescribed as an adjunct to antihypertensive therapy in patients with normal renal function. We have not measured T.B.K. in such patients but in two studies (Anderson et al., 1971; Graybiel and Sode, 1971 ) no significant reduction in T.B.K. was evident after two and 12 months respectively. Some studies have shown significant reductions in T.E.K. (Healy et al., 1970; Bartorelli et al., 1966; Winer, 1961) but the following comments may be made. In the study of Bartorelli et al. (1966) the dietary intake of potassium, estimated at only 30-40 mEq/day, was inadequate and the study lasted only 48 days. In another short-term study lasting four weeks (Winer, 1961) significant reductions in T.E.K. were found in some patients, but the dose of hydrochlorothiazide (150 mg) was higher than is often prescribed as an adjunct to antihypertensive therapy. The study of Healy et al. (1970) was longer (10-15 weeks), but though significant reductions in T.E.K. occurred the authors concluded that in the absence of any symptoms attributable to hypokalaemia these reductions were acceptable.
Hyperkalaemia, which is a potentially more dangerous condition than the mild hypokalaemia often associated with diuretic therapy, did not occur in any of the patients in this study who had renal impairment and who were given potassium supplements. Nevertheless, hyperkalaemia remains a potential hazard in such patients and it may not be coincidental that more deaths have been reported from this cause in patients treated with diuretics and potassium supplements than have been attributed to hypokalaemia (Lawson, 1974) .
The situation is different in oedematous conditions such as cardiac failure and cirrhosis of the liver. In cardiac failure (White, 1970; Flear, 1972; Edmondson et al., 1974) it has been shown that potassium depletion may be present possibly as a consequence of inability of the cell to accumulate potassium because of tissue anoxia, together with promotion of urinary potassium excretion due to secondary hyperaldosteronism (Flear, 1972) . Materson et al. (1970) have shown that potassium supplements or potassium sparing diuretics or both are indicated in patients with cirrhosis of the liver. Apart from this study we have made limited observations of T.B.K. in patients treated with much higher doses of frusemide (500-1000 mg). While marked reductions in T.B.K. were noted in two patients with cardiac failure in association with renal impairment no significant reductions occurred in three patients with the nephrotic syndrome who had normal or only slightly impaired renal function. This is in agreement with the hypothesis that, with respect to cardiac failure, potassium depletion may result from tissue anoxia rather than from the treatment given (Edmondson et al., 1974) . Though the role of potassium supplements in the nephrotic syndrome remains to be defined, in the specific circumstances of cardiac failure and cirrhosis of the liver it is widely accepted that potassium supplements should be given along with diuretic therapy.
